111 related articles for article (PubMed ID: 38412664)
1. XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant.
Van Berckelaer C; Van Laere S; Lee S; Morse MA; Geradts J; Dirix L; Kockx M; Bertucci F; Van Dam P; Devi GR
Transl Oncol; 2024 May; 43():101907. PubMed ID: 38412664
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
3. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
4. Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas.
El-Nadi M; Hassan H; Saleh ME; Nassar E; Ismail YM; Amer M; Greve B; Götte M; El-Shinawi M; Ibrahim SA
Matrix Biol Plus; 2020 May; 6-7():100030. PubMed ID: 33543027
[TBL] [Abstract][Full Text] [Related]
5. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.
Arora J; Sauer SJ; Tarpley M; Vermeulen P; Rypens C; Van Laere S; Williams KP; Devi GR; Dewhirst MW
Oncotarget; 2017 Apr; 8(16):25848-25863. PubMed ID: 28460441
[TBL] [Abstract][Full Text] [Related]
8. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
[TBL] [Abstract][Full Text] [Related]
9. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
[TBL] [Abstract][Full Text] [Related]
10. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.
Mohamed MM; El-Ghonaimy EA; Nouh MA; Schneider RJ; Sloane BF; El-Shinawi M
Int J Biochem Cell Biol; 2014 Jan; 46():138-47. PubMed ID: 24291763
[TBL] [Abstract][Full Text] [Related]
11. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer.
Jeong H; Hwang I; Kang SH; Shin HC; Kwon SY
J Breast Cancer; 2019 Mar; 22(1):38-51. PubMed ID: 30941232
[TBL] [Abstract][Full Text] [Related]
13. PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.
Armstrong CW; Maxwell PJ; Ong CW; Redmond KM; McCann C; Neisen J; Ward GA; Chessari G; Johnson C; Crawford NT; LaBonte MJ; Prise KM; Robson T; Salto-Tellez M; Longley DB; Waugh DJ
Oncotarget; 2016 Feb; 7(7):7885-98. PubMed ID: 26799286
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory Breast Cancer: The Secretome of HCMV
Mohamed HT; El-Sharkawy AA; El-Shinawi M; Schneider RJ; Mohamed MM
Front Oncol; 2022; 12():899622. PubMed ID: 35847899
[TBL] [Abstract][Full Text] [Related]
15. XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.
Evans MK; Brown MC; Geradts J; Bao X; Robinson TJ; Jolly MK; Vermeulen PB; Palmer GM; Gromeier M; Levine H; Morse MA; Van Laere SJ; Devi GR
Cancer Res; 2018 Apr; 78(7):1726-1738. PubMed ID: 29351901
[TBL] [Abstract][Full Text] [Related]
16. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
17. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
18. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
19. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
[TBL] [Abstract][Full Text] [Related]
20. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
